Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.065
Neutral
RSI(14)
41.796
Neutral
STOCH(KDJ)(9,3,3)
32.409
Sell
ATR(14)
0.075
High Vlolatility
CCI(14)
21.577
Neutral
Williams %R
83.815
Oversold
TRIX(12,20)
-0.930
Sell
StochRSI(14)
33.205
Sell
Collplant Biotechnologies Ltd
CLGN0.641USD
-0.019-2.88%
Market hours （ET）Quotes delayed by 15 min
8.15MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Collplant Biotechnologies Ltd
Currency: USD Updated: 2026-03-27Key Insights
Collplant Biotechnologies Ltd's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 171 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 11.00.In the medium term, the stock price is expected to trend down.Despite a good stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Collplant Biotechnologies Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Collplant Biotechnologies Ltd Highlights
StrengthsRisks
CollPlant Biotechnologies Ltd, formerly known as Collplant Holdings Ltd, is a company dealing in aesthetic medicine and regenerative medicine based in Israel. The company provides products and technologies for broadly understood regenerative medicine, including tissue regeneration and organ production. The technology is based on plants and is based on the production of collagen type I (rhCollagen).
Growing
The company is in a growing phase, with the latest annual income totaling USD 2.37M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 2.37M.
Overvalued
The company’s latest PE is -0.66, at a high 3-year percentile range.
Held by James Simons
Star Investor James Simons holds 17.60K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.72.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
11.000
Target Price
+1566.67%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-03-27The current financial score of Collplant Biotechnologies Ltd is 6.07, ranking 293 out of 391 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 60.00K, representing a year-over-year decrease of 63.41%, while its net profit experienced a year-over-year decrease of 17.30%.
Score
Financials
8.47
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.44
Operational Efficiency
2.84
Growth Potential
4.54
Shareholder Returns
7.08
Collplant Biotechnologies Ltd's Company Valuation
Currency: USD Updated: 2026-03-27The current valuation score of Collplant Biotechnologies Ltd is 6.79, ranking 220 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.66, which is -20.00% below the recent high of -0.53 and -1924.15% above the recent low of -13.41.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 171/391
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-03-27The current earnings forecast score of Collplant Biotechnologies Ltd is 7.00, ranking 312 out of 391 in the Biotechnology & Medical Research industry. The average price target is 11.50, with a high of 12.00 and a low of 11.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
11.000
Target Price
+1566.67%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
548
Total
6
Median
6
Average
Company name
Ratings
Analysts
Collplant Biotechnologies Ltd
CLGN
2
CRISPR Therapeutics AG
CRSP
29
IQVIA Holdings Inc
IQV
27
argenx SE
ARGX
26
Beigene Ltd
ONC
24
Intellia Therapeutics Inc
NTLA
24
1
2
3
...
110
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-03-27The current price momentum score of Collplant Biotechnologies Ltd is 5.81, ranking 297 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 0.82 and the support level at 0.46, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
0.670
Sell
MA10
0.640
Buy
MA20
0.621
Buy
MA50
0.937
Sell
MA100
1.381
Sell
MA200
1.817
Sell
Institutional Confidence
Currency: USD Updated: 2026-03-27The current institutional shareholding score of Collplant Biotechnologies Ltd is 3.00, ranking 195 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 18.05%, representing a quarter-over-quarter decrease of 0.21%. The largest institutional shareholder is James Simons, holding a total of 17.60K shares, representing 0.14% of shares outstanding, with 69.29% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-03-27The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Collplant Biotechnologies Ltd is 2.49, ranking 221 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 0.89. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
0.89
VaR
+7.33%
240-Day Maximum Drawdown
+88.00%
240-Day Volatility
+139.29%
Return
Best Daily Return
60 days
+24.18%
120 days
+24.18%
5 years
+76.17%
Worst Daily Return
60 days
-53.42%
120 days
-53.42%
5 years
-53.42%
Sharpe Ratio
60 days
-1.34
120 days
-1.71
5 years
-0.31
Risk Assessment
Maximum Drawdown
240 days
+88.00%
3 years
+93.38%
5 years
+97.58%
Return-to-Drawdown Ratio
240 days
-0.85
3 years
-0.33
5 years
-0.20
Skewness
240 days
+1.68
3 years
+2.07
5 years
+1.83
Volatility
Realised Volatility
240 days
+139.29%
5 years
+98.66%
Standardised True Range
240 days
+31.72%
5 years
+80.80%
Downside Risk-Adjusted Return
120 days
-180.32%
240 days
-180.32%
Maximum Daily Upside Volatility
60 days
+129.35%
Maximum Daily Downside Volatility
60 days
+136.76%
Liquidity
Average Turnover Rate
60 days
+0.68%
120 days
+0.61%
5 years
--
Turnover Deviation
20 days
+72.18%
60 days
+200.82%
120 days
+172.79%
Peer Comparison
Biotechnology & Medical Research
Collplant Biotechnologies Ltd
CLGN
5.65 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.42 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Madrigal Pharmaceuticals Inc
MDGL
8.27 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.27 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Day One Biopharmaceuticals Inc
DAWN
8.26 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.21 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
